Latest Phase III OA readout boosts Ampio shares

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) added $0.58 (33%) to $2.33 on Thursday after reporting that Ampion met the primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis of the knee. Ampio hopes to meet with FDA next quarter, after which the company plans to submit a BLA for Ampion to treat signs and symptoms of severe OA of the knee.

Ampion has previously met the primary endpoint in the Phase III SPRING trial to treat OA of the knee, but missed the primary endpoint in the Phase III STRIDE and PIVOT trials in the indication (see BioCentury Extra, Aug. 14, 2013; April 20, 2015; & June 30, 2016)...